Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Effects of Gluten Digestion With ALV003
Scientific title
A Phase 0 Study in Subjects With Well Controlled Celiac Disease to Assess the Effects of Gluten Digestion With ALV003 (a Protease Enzyme) in Vitro
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Celiac Disease 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Study type
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
1 - Active - This group received gluten pre-treated with ALV003

2 - Placebo - This group received Gluten pre-treated with placebo.

Comparator / control treatment
Control group

Primary outcome [1] 0 0
The clinical response by symptom measurement before and after oral challenge
Timepoint [1] 0 0
Day 1 and Day 6
Primary outcome [2] 0 0
The immune response measured by ELISPOT testing and celiac disease serology
Timepoint [2] 0 0
Prior to and post 3-day gluten challenge
Secondary outcome [1] 0 0
Describe the immunotoxic epitope profile of gluten digests with ALV003 compared with placebo
Timepoint [1] 0 0
Day 1 and Day 14

Key inclusion criteria
- Age 18-75 years

- Well controlled Celiac Disease without flare in symptoms for the past 8 weeks

- History of biopsy proven Celiac Disease

- Able and willing to complete a symptom diary for 3 days prior and through 3 days post
gluten challenge

- Been on a gluten free diet for 8 weeks prior to study entry

- Have normal celiac serology (anti- tTG level of <20 units/mL)
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Uncontrolled complications of celiac disease which in the opinion of the Investigator
would impact their immune response, or pose an increased risk to the subject.
(example: like type 1 diabetes or other autoimmune disease)

- Pregnant or breast feeding women, subjects of childbearing potential to use two
methods of contraception

- Concomitant medications such as over the counter digestive enzymes, immunosuppressive
therapies, anticoagulants, NSAIDs. Chronic medications for well-controlled chronic
conditions are allowed.

- Clinically significant abnormal lab values, as determined by the PI:

- Untreated or active peptic ulcer disease, esophagitis, motility disorders or any
gastrointestinal diseases.

- Positive pregnancy test within 7 days prior to study drug administration

- Known allergy or hypersensitivity to E.coli or E.coli derived proteins

Study design
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Nucleus Networks Limited - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Alvine Pharmaceuticals Inc.

Ethics approval
Ethics application status

Brief summary
This is a Phase 0, Double-blind study that will assess the effect of in vitro treatment of
gluten with ALV003 or with placebo when ingested by CD Subjects.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Gregor Brown, MD
Address 0 0
The Alfred
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications